Literature DB >> 10334204

The level of DNA modification by (+)-syn-(11S,12R,13S,14R)- and (-)-anti-(11R,12S,13S,14R)-dihydrodiol epoxides of dibenzo[a,l]pyrene determined the effect on the proteins p53 and p21WAF1 in the human mammary carcinoma cell line MCF-7.

A Luch1, K Kudla, A Seidel, J Doehmer, H Greim, W M Baird.   

Abstract

The polycyclic aromatic hydrocarbon (PAH) dibenzo[a,l]pyrene (DB[a,l]P), the most carcinogenic PAH tested in rodent bioassays, exerts its pathobiological activity via metabolic formation of electrophilically reactive DNA-binding fjord region (+)-syn-(11S,12R,13S,14R)- or (-)-anti-(11R,12S,13S,14R)-DB[a,l]P-dihydrodiol epoxides (DB[a,l]-PDEs). DB[a,l]P is metabolized to these DB[a,l]PDEs which bind to DNA in human mammary carcinoma MCF-7 cells. The molecular response of MCF-7 cells to DNA damage caused by DB[a,l]PDEs was investigated by analyzing effects on the expression of the tumor suppressor protein p53 and one of its target gene products, the cyclin-dependent kinase inhibitor p21WAF1. Treatment of MCF-7 cells with (+)-syn- and (-)-anti-DB[a,l]PDE at a concentration range of 0.001-0.1 microM resulted in DB[a,l]PDE-DNA adduct levels between 2 and 30, and 3 and 80 pmol/mg DNA, respectively, 8 h after exposure. (-)-anti-DB[a,l]PDE exhibited a higher binding efficiency that correlated with a significantly stronger p53 response at low concentrations of the dihydrodiol epoxides. The level of p53 increased by 6-8 h after treatment. The p21WAF1 protein amount exceeded control levels by 12 h and remained elevated for 96 h. At a dose of 0.01 microM (+)-syn-DB[a,l]PDE, an increase in p21WAF1 was observed in the absence of a detectable change in p53 levels. The results indicate that the increase in p53 induced by DB[a,l]PDEs in MCF-7 cells requires an adduct level of approximately 15 pmot/mg DNA and suggest that the level of adducts rather than the specific structure of the DB[a,l]PDE-DNA adduct formed triggers the p53 response. The PAH-DNA adduct level formed may determine whether p53 and p21VAF1 pathways respond, resulting in cell-cycle arrest, or fail to respond and increase the risk of mutation induction by these DNA lesions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334204     DOI: 10.1093/carcin/20.5.859

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  Response of human mammary epithelial cells to DNA damage induced by 4-hydroxyequilenin: Lack of p53-mediated G1 arrest.

Authors:  Muriel Cuendet; Judy L Bolton
Journal:  Chem Biol Interact       Date:  2006-04-28       Impact factor: 5.192

2.  Benzo[a]pyrene diol epoxide stimulates an inflammatory response in normal human lung fibroblasts through a p53 and JNK mediated pathway.

Authors:  Kristian Dreij; Kahn Rhrissorrakrai; Kristin C Gunsalus; Nicholas E Geacintov; David A Scicchitano
Journal:  Carcinogenesis       Date:  2010-04-09       Impact factor: 4.944

3.  Involvement of nuclear factor of activated T cells 3 (NFAT3) in cyclin D1 induction by B[a]PDE or B[a]PDE and ionizing radiation in mouse epidermal Cl 41 cells.

Authors:  Jin Ding; Ronghe Zhang; Jingxia Li; Caifang Xue; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2006-04-28       Impact factor: 3.396

4.  Induction of ovarian cancer and DNA adducts by Dibenzo[a,l]pyrene in the mouse.

Authors:  Kun-Ming Chen; Shang-Min Zhang; Cesar Aliaga; Yuan-Wan Sun; Timothy Cooper; Krishnegowda Gowdahalli; Junjia Zhu; Shantu Amin; Karam El-Bayoumy
Journal:  Chem Res Toxicol       Date:  2012-01-06       Impact factor: 3.739

5.  Curcumin and vitamin E protect against adverse effects of benzo[a]pyrene in lung epithelial cells.

Authors:  Wenbin Zhu; Meghan M Cromie; Qingsong Cai; Tangfeng Lv; Kamaleshwar Singh; Weimin Gao
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

6.  Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer.

Authors:  Yozo Mitsui; Inik Chang; Taku Kato; Yutaka Hashimoto; Soichiro Yamamura; Shinichiro Fukuhara; Darryn K Wong; Marisa Shiina; Mitsuho Imai-Sumida; Shahana Majid; Sharanjot Saini; Hiroaki Shiina; Koichi Nakajima; Guoren Deng; Rajvir Dahiya; Yuichiro Tanaka
Journal:  Oncotarget       Date:  2016-08-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.